Enochian Biosciences Inc (OTCMKTS:ENOB)’s share price rose 10.9% during trading on Wednesday . The stock traded as high as $6.20 and last traded at $5.28, approximately 117,524 shares changed hands during mid-day trading. An increase of 138% from the average daily volume of 49,381 shares. The stock had previously closed at $4.76.
The company has a 50 day simple moving average of $4.65 and a 200 day simple moving average of $5.73.
Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in Enochian Biosciences by 5.3% in the second quarter. Vanguard Group Inc. now owns 535,607 shares of the company’s stock valued at $2,411,000 after purchasing an additional 27,039 shares during the last quarter. BlackRock Inc. boosted its holdings in Enochian Biosciences by 316.8% in the second quarter. BlackRock Inc. now owns 221,718 shares of the company’s stock valued at $998,000 after purchasing an additional 168,520 shares during the last quarter. Susquehanna International Group LLP purchased a new position in Enochian Biosciences in the second quarter valued at about $133,000. United Capital Financial Advisers LLC purchased a new position in Enochian Biosciences in the second quarter valued at about $105,000. Finally, Wells Fargo & Company MN purchased a new position in Enochian Biosciences in the second quarter valued at about $72,000.
Enochian Biosciences Inc, a biopharmaceutical company, identifies, develops, manufactures, and commercializes gene therapies for HIV/AIDS and cancer patients. Its lead candidate include ENO-1001 a genetically modified cell therapy for patients with HIV/AIDS. It is also developing ENO-2001, an HIV vaccine; and additional compounds, such as ENO-4001, ENO-4002, ENO-3001, and ENO-5001 that are in discovery stage for prevention of relapse in colon cancer patients.
Receive News & Ratings for Enochian Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enochian Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.